Paediatric Immunization Schedule - India

Chronological NIS & IAP Vaccination Timeline in Paediatrics
⚙ Workflow: Enter the child's exact Date of Birth or current age, then select NIS or IAP. The engine will synthesise a complete longitudinal timeline, muting completed past milestones and highlighting the current due vaccines along with clinical pearls.

1. Child Age Parameters

2. Target Immunization Schedule

◆ Clinical Pearls & Protocols

Mnemonics

Freeze-Sensitive Vaccines (Do NOT Freeze):
Remember: "Never Freeze P-H-D"
• P: Pentavalent, PCV, Polio (IPV/fIPV)
• H: Hepatitis B, Hib
• D: DPT, DTaP, Td
Mechanism: Freezing destroys the aluminium hydroxide adjuvant lattice irreversibly. Perform the Shake Test against a known frozen control to detect compromised vials.
Live Attenuated Vaccines (Avoid in severe immunocompromise):
Remember: "B-R-O-M-J"
• BCG
• Rotavirus
• OPV
• Measles / MR / MMR / Mumps / Varicella
• Japanese Encephalitis (live variant)
Two or more injectable live vaccines must be given either on the same day or separated by a minimum of 4 weeks to prevent immune interference.
Birth Dose Mnemonic: "BOH"
• BCG
• OPV-0 (Zero dose)
• Hepatitis B Birth Dose (within 24 hours)
The HepB birth dose is the most time-critical vaccine in the entire schedule. Delay beyond 24 hours significantly reduces efficacy in preventing vertical (mother-to-child) transmission.

The Pentavalent Target Diseases

The liquid Pentavalent vaccine (DTwP-HepB-Hib) drastically reduced the injection burden. Residents must instantly recognise the clinical presentations of these highly lethal, yet entirely preventable, conditions.

Component Antigen Type Classic Illness Script (Clinical Presentation) Indian Context / Burden
Diphtheria Toxoid Low-grade fever, severe sore throat, adherent grey pseudomembrane bleeding on scraping, 'bull neck' (lymphadenopathy), myocarditis. Resurgence noted. 968 cases reported nationally (HMIS 2021-22). Outbreaks shifting to older adolescents with waning immunity.
Pertussis Whole-Cell (Killed) Coryza followed by paroxysmal staccato cough, high-pitched inspiratory 'whoop', post-tussive emesis. Extreme leukocytosis (>20,000/μL). High morbidity in unimmunised infants. Apnoea (not cough) is the primary presentation in neonates.
Tetanus Toxoid Descending spastic paralysis, trismus (lockjaw), risus sardonicus, opisthotonos. Preserved sensorium throughout. Maternal & Neonatal Tetanus officially eliminated in India (2016). Risk persists in unvaccinated adults with contaminated wounds.
Hepatitis B Recombinant (HBsAg) Insidious jaundice, hepatomegaly, elevated AST/ALT. High risk of chronicity if acquired perinatally (>90%). Endemic. 3 to 4% chronic carrier rate. Leading cause of hepatocellular carcinoma in India.
Hib Conjugate Polysaccharide Acute bacterial meningitis, acute epiglottitis (drooling, stridor, tripod position), pneumonia, septic arthritis. Historically the leading cause of bacterial meningitis in Indian children under 5 years.

Administration Route & Site Matrix

⚠ Important Warning: Never administer intramuscular (IM) vaccines in the gluteal region for infants. The erratic absorption due to deep gluteal fat and the high risk of sciatic nerve injury make the anterolateral mid-thigh the only acceptable IM site for children under 3 years. This is a common error in Indian clinical practice and must be actively corrected.
Route Vaccines / Therapeutics Exact Site & Technique
Intradermal (ID) BCG, fIPV BCG: Left upper arm (tubercle syringe).
fIPV: Right upper arm.
Technique: 15° angle, bevel up. Must produce a distinct pale wheal (peau d'orange).
Intramuscular (IM) Pentavalent, PCV, HepB, DPT Boosters, Td, Tdap, TCV, IPV, HPV Infants/Toddlers: Anterolateral mid-thigh (Vastus lateralis).
Older Children (>3y): Deltoid muscle.
Technique: 90° angle. Deep into the muscle bulk. Needle gauge: 23-25G.
Subcutaneous (SC) MR / MMR, JE, Varicella MR: Right upper arm.
JE: Left upper arm.
Technique: 45° angle into pinched subcutaneous tissue.
Oral OPV, Rotavirus (RVV), Vitamin A, Albendazole Oral mucosa.
Pearl: For young children (1-3 yrs), Albendazole tablets MUST be crushed and mixed with safe water to prevent choking. If an infant regurgitates the OPV/RVV dose immediately, repeat after 5 minutes.

NIS vs IAP Schedule: Key Differences

Clinical Context: The NIS is the government schedule under UIP (free, public sector, optimised for maximum epidemiological impact at population level). The IAP schedule is recommended for private practitioners and offers extended individual coverage with additional vaccines.
Feature NIS (Government) IAP (Private Sector)
Polio Strategy OPV + 3 fractional IPV doses (6wk, 14wk, 9m) Full-dose IPV at 6, 10, 14 wk + boosters; OPV as per NIS campaigns
DPT Type Whole-cell pertussis (DTwP) in Pentavalent DTwP or DTaP; DTaP (acellular) has less reactogenicity but potentially shorter duration of immunity
Typhoid Not in NIS TCV from 6 to 9 months (catch-up to 15 yr)
Measles/Mumps MR only (Measles-Rubella) MMR at 9 months, 15 months, 4 to 6 years (Adds Mumps protection)
Influenza Not in NIS Annual from 6 months; 2 doses 4 wk apart for first-time recipients under 9 yr
Hepatitis A Not in NIS 2 doses: 12 months + 18 months (killed vaccine)
Varicella Not in NIS 2 doses: 15 months + 4 to 6 years
HPV Introduced for girls 9 to 14 years in UIP (2023) All adolescents 9 to 14 yr; 2 doses, 6 months apart

AEFI: Adverse Events Following Immunization

⚠ Mandatory Reporting: All serious AEFIs must be reported within 24 hours to the District Immunization Officer (DIO) and entered into the cMhealthApp/AEFI module. Do not dismiss parental AEFI concerns. Document meticulously.
AEFI Type Examples Action
Minor (Expected) Local pain/swelling, low-grade fever (<38.5°C), irritability for 24 to 48 hours Reassure parents. Paracetamol 10 to 15 mg/kg PRN. NOT a contraindication to future doses.
Severe (Non-Serious) High fever (>39°C), excessive crying (>3 hours), large local reaction (>5 cm) Document. Symptomatic management. Consider DTaP for future DPT doses if whole-cell caused the reaction.
Serious Anaphylaxis (within 30 min), HHE (Hypotonic-Hyporesponsive Episode), intussusception (post-RVV), BCG-osis MANDATORY AEFI REPORT. Manage anaphylaxis per protocol (IM Adrenaline 0.01 ml/kg of 1:1000). Hospital admission.

Catch-Up Rules & Cold Chain Integrity

✓ The Interruption Rule: Never restart a delayed vaccine series. Immunologic memory dictates that you simply continue from where the schedule was interrupted, maintaining standard minimum intervals between doses.
Key Catch-Up Intervals:
• Minimum interval between primary Pentavalent/OPV/RVV doses: strictly 4 weeks. Giving it earlier invalidates the dose.
• Rotavirus upper limits: First dose must not be initiated after 14 weeks 6 days. Series must be completed by 1 year of age.
• Freeze Warning: Pentavalent, HepB, Td, DPT, PCV, and IPV are adsorbed on aluminium adjuvants. Freezing destroys potency irreversibly. If freezing is suspected, perform the Shake Test.
• Open Vial Policy: Opened multi-dose liquid vaccines (OPV, HepB, DPT, Td, Pentavalent, PCV) can be used for up to 28 days if stored at +2 to +8 °C with VVM intact. Reconstituted lyophilised vaccines (BCG, MR, JE) must be discarded within 4 hours.

Pharmaceutical Marketing Awareness

⚠ Evidence-Based Guidance for Residents:
• DTaP vs DTwP: DTaP is aggressively marketed as "painless" but evidence shows DTwP (whole-cell) confers more durable immunity. DTaP is acceptable but not automatically superior. Counsel parents objectively.
• Combination vaccines: Hexavalent/pentavalent combinations reduce injection burden but are significantly more expensive. Choose based on family affordability, not marketing incentives.
• Unnecessary boosters: There is no evidence for annual Typhoid "booster" shots marketed by some vaccine manufacturers. TCV provides protection for at least 5 years with a single dose.
Abbreviations: ACVIP (Advisory Committee on Vaccines and Immunization Practices) · AEFI (Adverse Event Following Immunization) · ALT (Alanine Aminotransferase) · AST (Aspartate Aminotransferase) · BCG (Bacillus Calmette-Guérin) · DIO (District Immunization Officer) · DPT (Diphtheria, Pertussis, Tetanus) · DTaP (Acellular Pertussis) · DTwP (Whole-cell Pertussis) · fIPV (Fractional Inactivated Polio Vaccine) · GA4 (Google Analytics 4) · HBsAg (Hepatitis B surface Antigen) · HepA (Hepatitis A) · HepB (Hepatitis B) · HHE (Hypotonic-Hyporesponsive Episode) · Hib (Haemophilus influenzae type b) · HMIS (Health Management Information System) · HPV (Human Papillomavirus) · IAP (Indian Academy of Pediatrics) · ID (Intradermal) · IM (Intramuscular) · IPV (Inactivated Polio Vaccine) · JE (Japanese Encephalitis) · MR (Measles-Rubella) · MMR (Measles, Mumps, Rubella) · NIS (National Immunization Schedule) · OPV (Oral Polio Vaccine) · PCV (Pneumococcal Conjugate Vaccine) · RVV (Rotavirus Vaccine) · SBAR (Situation, Background, Assessment, Recommendation) · SC (Subcutaneous) · TCV (Typhoid Conjugate Vaccine) · Td (Tetanus & adult Diphtheria) · Tdap (Tetanus, Diphtheria, acellular Pertussis) · TT (Tetanus Toxoid) · UIP (Universal Immunization Programme) · VVM (Vaccine Vial Monitor)
Algorithm References & Evidence Base
  1. Ministry of Health and Family Welfare, Government of India. Universal Immunization Programme: National Immunization Schedule. Immunization Division, MoHFW; 2024.
  2. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP). IAP Guidebook on Immunization 2023-2025. Eds: Kasi SG, et al. New Delhi: Jaypee Brothers; 2024.
  3. Ministry of Health and Family Welfare. Immunization Handbook for Medical Officers. Government of India; 2017 (updated 2022).
  4. World Health Organization. WHO Recommendations for Routine Immunization - Summary Tables. Geneva: WHO; 2024.
  5. National Technical Advisory Group on Immunization (NTAGI), India. Recommendations on PCV and HPV Introduction in UIP. MoHFW; 2023.
How to Cite This Tool

AMA Style:
Umakanth S. Indian Immunization Schedule Advisor. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Indian Immunization Schedule Advisor [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

⚠ Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by
Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Immunisation & Prophylaxis
Specialties Pediatrics, Immunology
Status Essential
Related Clinical Tools
Adult Immunisation AdvisorTetanus Wound Prophylaxis AdvisorHPV Vaccination Advisor
Back to All Medical Calculators & Pathways